Thompson Erin L, Rao P S S, Hayes Christopher, Purtill Catherine
1 Department of Pharmacy Practice, The University of Findlay, Findlay, OH, USA.
2 Department of Pharmaceutical Sciences, The University of Findlay, Findlay, OH, USA.
J Pharm Pract. 2019 Aug;32(4):412-421. doi: 10.1177/0897190018759225. Epub 2018 Feb 25.
The Centers for Disease Control and Prevention (CDC) reports a 200% escalation in the rate of opioid overdose deaths in the United States. Unfortunately, Ohio has been deemed the epicenter of the nation's opioid epidemic. In 2015, Ohio passed a bill that permits a pharmacist to distribute naloxone without a prescription.
This survey was aimed to discover pharmacists' knowledge of naloxone and Ohio law, perceived barriers that may prohibit naloxone dispensing, and Ohio pharmacists' general confidence, comfort, perception, and experience dispensing naloxone per physician protocol.
Pharmacists' knowledge of naloxone and Ohio law pertaining to dispensing naloxone; perceived barriers to naloxone distribution; and overall experience, willingness, comfort, and perceptions of personally supplying naloxone were assessed using multiple-choice and Likert-type scale questions through an e-mail survey.
Overall, Ohio pharmacists were knowledgeable about naloxone and displayed confidence in their training and ability to provide patient education on naloxone. Pharmacists were less certain about Ohio law pertaining to naloxone distribution, especially those who have been in practice longer. Pharmacists indicated several barriers to dispensing naloxone and the need for more training. Younger pharmacists were more likely to report a concern with clientele who would frequent their pharmacy and moral and ethical concerns as barriers to dispensing naloxone.
Additional educational programs should be delivered to Ohio pharmacists to inform them of the state law and policies. Continuing education programs that review substance abuse and attempt to reduce social stigma may assist with increasing naloxone distribution to those in need, especially, if directed toward younger pharmacists in Ohio.
美国疾病控制与预防中心(CDC)报告称,美国阿片类药物过量致死率增长了200%。不幸的是,俄亥俄州被视为美国阿片类药物流行的中心。2015年,俄亥俄州通过了一项法案,允许药剂师无需处方即可分发纳洛酮。
本次调查旨在了解药剂师对纳洛酮和俄亥俄州法律的了解情况、可能阻碍纳洛酮分发的感知障碍,以及俄亥俄州药剂师按照医生方案分发纳洛酮的总体信心、舒适度、认知和经验。
通过电子邮件调查,使用多项选择题和李克特量表式问题,评估药剂师对纳洛酮和俄亥俄州有关分发纳洛酮法律的了解;纳洛酮分发的感知障碍;以及个人提供纳洛酮的总体经验、意愿、舒适度和认知。
总体而言,俄亥俄州的药剂师对纳洛酮有所了解,并对自己提供纳洛酮患者教育的培训和能力充满信心。药剂师对俄亥俄州有关纳洛酮分发的法律不太确定,尤其是那些从业时间较长的药剂师。药剂师指出了分发纳洛酮的几个障碍以及对更多培训的需求。年轻药剂师更有可能报告担心经常光顾其药房的顾客以及道德伦理问题是分发纳洛酮的障碍。
应为俄亥俄州的药剂师提供更多教育项目,使其了解该州的法律和政策。审查药物滥用并试图减少社会污名的继续教育项目可能有助于增加向有需要者分发纳洛酮,特别是如果针对俄亥俄州的年轻药剂师。